FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3099002519> ?p ?o ?g. }

• W3099002519 abstract "Background A recent phase III study (Keynote-048) demonstrated survival benefit of platinum, 5-FU and pembrolizumab in 1st line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (RM-HNSCC). 1 However, administration of 5-FU has been a challenge for logistics and toxicities. As platinum, paclitaxel and pembrolizumab has been shown to be an effective and safe treatment for non-small cell lung cancer, 2 we hypothesized that carboplatin, paclitaxel and pembrolizumab would be safe and effective for 1st line treatment of RM-HNSCC. Methods We performed a retrospective study of RM-HNSCC patients who received carboplatin, paclitaxel and pembrolizumab for first line systemic therapy, treated between December 2015 and January 2020 at the University of California, San Francisco. Patients who received at least 1 cycle of treatment with pre-treatment and post-treatment images were included in the analyses. Response to the treatment was assessed using RECIST criteria version 1.1. We also estimated overall survival and progression free survival using Kaplan-Meier method. Results Nine patients who received carboplatin, paclitaxel and pembrolizumab as first line systemic therapy for RM-HNSCC were identified. Two patients had HPV positive oropharyngeal SCC, the other patients unknown primary SCC in head and neck (2), oral cavity SCC (2), laryngeal SCC (1), hypopharyngeal SCC (1) and SCC of orbit (1). There were 1 complete response (CR, 11%), 6 partial responses (PR, 55%), 1 stable disease (SD, 11%) and 1 progressive disease (PD, 11%). Overall response rate (ORR) was 78%, and median progression free survival and median overall survival have not reached with median follow-ups of 6 months and 8 months, respectively. Two patients discontinued chemotherapy after 1 cycle for grade 4 acute kidney injury and grade 4 anaphylaxis, yet achieved CR and PR, respectively. Conclusions The retrospective analysis suggests that first line carboplatin, paclitaxel and pembrolizumab for RM-HNSCC is an active regimen and can be considered in place of platinum, 5-FU and pembrolizumab, which merits further investigation. Ethics Approval The study was approved by UCSF’s Institutional Review Board, approval number 19-29365. References Burtness B, Harrington K, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394:1915–1928. Paz-Ares L, Luft A, Vincente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer. New Engl J Med 2018; 379:2040–2051." @default.
• W3099002519 created "2020-11-23" @default.
• W3099002519 creator A5008258990 @default.
• W3099002519 creator A5032124327 @default.
• W3099002519 creator A5042334543 @default.
• W3099002519 creator A5071669347 @default.
• W3099002519 creator A5072582710 @default.
• W3099002519 creator A5076428462 @default.
• W3099002519 date "2020-11-01" @default.
• W3099002519 modified "2023-09-27" @default.
• W3099002519 title "201 Carboplatin, paclitaxel and pembrolizumab for the first line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma" @default.
• W3099002519 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0201" @default.
• W3099002519 hasPublicationYear "2020" @default.
• W3099002519 type Work @default.
• W3099002519 sameAs 3099002519 @default.
• W3099002519 citedByCount "2" @default.
• W3099002519 countsByYear W30990025192021 @default.
• W3099002519 countsByYear W30990025192022 @default.
• W3099002519 crossrefType "proceedings-article" @default.
• W3099002519 hasAuthorship W3099002519A5008258990 @default.
• W3099002519 hasAuthorship W3099002519A5032124327 @default.
• W3099002519 hasAuthorship W3099002519A5042334543 @default.
• W3099002519 hasAuthorship W3099002519A5071669347 @default.
• W3099002519 hasAuthorship W3099002519A5072582710 @default.
• W3099002519 hasAuthorship W3099002519A5076428462 @default.
• W3099002519 hasConcept C121608353 @default.
• W3099002519 hasConcept C126322002 @default.
• W3099002519 hasConcept C141071460 @default.
• W3099002519 hasConcept C143998085 @default.
• W3099002519 hasConcept C2776530083 @default.
• W3099002519 hasConcept C2776694085 @default.
• W3099002519 hasConcept C2776833033 @default.
• W3099002519 hasConcept C2777292972 @default.
• W3099002519 hasConcept C2777701055 @default.
• W3099002519 hasConcept C2778239845 @default.
• W3099002519 hasConcept C2780057760 @default.
• W3099002519 hasConcept C2781451048 @default.
• W3099002519 hasConcept C3018411727 @default.
• W3099002519 hasConcept C3019992690 @default.
• W3099002519 hasConcept C509974204 @default.
• W3099002519 hasConcept C71924100 @default.
• W3099002519 hasConceptScore W3099002519C121608353 @default.
• W3099002519 hasConceptScore W3099002519C126322002 @default.
• W3099002519 hasConceptScore W3099002519C141071460 @default.
• W3099002519 hasConceptScore W3099002519C143998085 @default.
• W3099002519 hasConceptScore W3099002519C2776530083 @default.
• W3099002519 hasConceptScore W3099002519C2776694085 @default.
• W3099002519 hasConceptScore W3099002519C2776833033 @default.
• W3099002519 hasConceptScore W3099002519C2777292972 @default.
• W3099002519 hasConceptScore W3099002519C2777701055 @default.
• W3099002519 hasConceptScore W3099002519C2778239845 @default.
• W3099002519 hasConceptScore W3099002519C2780057760 @default.
• W3099002519 hasConceptScore W3099002519C2781451048 @default.
• W3099002519 hasConceptScore W3099002519C3018411727 @default.
• W3099002519 hasConceptScore W3099002519C3019992690 @default.
• W3099002519 hasConceptScore W3099002519C509974204 @default.
• W3099002519 hasConceptScore W3099002519C71924100 @default.
• W3099002519 hasLocation W30990025191 @default.
• W3099002519 hasOpenAccess W3099002519 @default.
• W3099002519 hasPrimaryLocation W30990025191 @default.
• W3099002519 hasRelatedWork W1969860488 @default.
• W3099002519 hasRelatedWork W1992461309 @default.
• W3099002519 hasRelatedWork W2013098021 @default.
• W3099002519 hasRelatedWork W2014060951 @default.
• W3099002519 hasRelatedWork W2244976797 @default.
• W3099002519 hasRelatedWork W2744360102 @default.
• W3099002519 hasRelatedWork W2996552572 @default.
• W3099002519 hasRelatedWork W3000701650 @default.
• W3099002519 hasRelatedWork W3011871240 @default.
• W3099002519 hasRelatedWork W3186092871 @default.
• W3099002519 isParatext "false" @default.
• W3099002519 isRetracted "false" @default.
• W3099002519 magId "3099002519" @default.
• W3099002519 workType "article" @default.